This week we take a (brief) stop back in time to the beginning of dostarlimab's journey that has ended (for now) in an accelerated approval for rectal cancer that is mismatch repair-deficient or high in micro-satellite instability (MMRd/h-MSI).
Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Altri episodi di "OncoPharm"



Non perdere nemmeno un episodio di “OncoPharm”. Iscriviti all'app gratuita GetPodcast.








